Correction to: Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis: In Relapsing-Remitting Multiple Sclerosis (CNS Drugs, (2011), 25, 3, (239-249), 10.2165/11204740-000000000-00000);Cladribine tablets: In relapsing-remitting multiple sclerosis

CNS Drugs

Volumn 25, Issue 3, 2011, Pages 239-249

  Muir, Victoria J ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Cladribine, general; Multiple sclerosis

Indexed keywords

CLADRIBINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GADOLINIUM; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; COCCIDIOIDOMYCOSIS; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DOUBLE BLIND PROCEDURE (TOPIC); DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PANCREAS CARCINOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEPSIS; TERATOGENICITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UROSEPSIS; UTERINE CERVIX CARCINOMA IN SITU; UTERUS MYOMA;

EID: 79951797436     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-020-00712-w     Document Type: Erratum

References (44)

1. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006 Mar 4; 332 (7540): 525-7. (Pubitemid 44364370)
2. The European Multiple Sclerosis Platform. Multiple sclero-sis-fact sheet [online]. Available from URL: http://www. ms-in-europe.org/multiple-sclerosis/ index.php?kategorie= whatisms&cnr=6&anr=127 [Accessed 2011 Jan 28].
3. Compston A, Coles A. Multiple sclerosis. Lancet 2008 Oct 25; 372 (9648): 1502-17.
4. Rudick RA, Polman CH. Current approaches to the iden-tification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009 Jun; 8 (6): 545-59.
5. Kieseier BC, Wiendl H. Oral disease-modifying treatments for multiple sclerosis: the story so far. CNS Drugs 2007; 21 (6): 483-502. (Pubitemid 46849184)
6. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68 (17): 2445-68.
7. Kopadze T, Dobert M, Leussink VI, et al. Cladribine im-pedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol 2009 Mar; 16 (3): 409-12.
8. Bennett JL, Stuve O. Update on inflammation, neurode-generation, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 2009; 32 (3): 121-32.
9. Langtry HD, Lamb HM. Cladribine: a review of its use in multiple sclerosis. Biodrugs 1998 May; 9 (5): 419-33. (Pubitemid 28216222)
10. Janssen-Cilag Ltd. Leustat injection: summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/emc/medicine/6737/SPC/ Leustat++ Injection./[Accessed 2011 Jan 28].
11. European Medicines Agency. Scientific discussion for the approval of Litak [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000504/WC500041660.pdf [Accessed 2011 Jan 28].
12. Bryson HM, Sorkin EM. Cladribine. A review of its phar-macodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies. Drugs 1993 Nov; 46 (5): 872-94. (Pubitemid 23329963)
13. Giovannoni G, Comi G, Cook S, et al. A placebocontrolled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362 (5): 416-26.
14. Australian Therapeutic Goods Administration. Australian public assessment report for cladribine tablets [online]. Available from URL: http://www.tga.gov.au/pmeds/aus par/auspar-movectro.pdf [Accessed 2011 Jan 28].
15. Merck KGaA. Merck KGaA announces outcome of its re-quest for reexamination of CHMP opinion for cladribine tablets in MS [online]. Available from URL: http://news. merck.de/N/0/9FA165BECF4916A8C125781E0065C3B1/ $File/Clad2011-e.pdf [Accessed 2011 Jan 28].
16. Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983 Oct; 62 (4): 737-43. (Pubitemid 13008659)
17. Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine ki-nase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980 Nov; 77 (11): 6865-9. (Pubitemid 11219046)
18. 0-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993 Feb 1; 81 (3): 597-601. (Pubitemid 23040848)
19. 0-deoxyadenosine and 9-b-D-arabinosyl-2-fluoro-adenine. Blood 1993 Jan 1; 81 (1): 143-50. (Pubitemid 23013688)
20. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989 Dec 15; 49 (24 Pt 1): 6923-8. (Pubitemid 20016568)
21. Soelberg-Sørensen PS, Comi G, Cook S, et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebocontrolled CLARITY study [abstract no. P472 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 9-12; Dusseldorf.
22. Rieckmann P, Comi G, Cook S, et al. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebocontrolled clarity study [abstract no. P816 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 9-12; Dusseldorf.
23. Soelberg-Sørensen PS, Rieckmann P, Comi G, et al. Effects of cladribine tablets on circulating lymphocyte subset re-constitution in the 96-week CLARITY study in relapsing-remitting multiple sclerosis (RRMS) [abstract no. P04.219 plus poster]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10-17; Toronto (ON).
24. Salvat C, Curchod M, Guedj E, et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis [abstract no. P280 plus poster]. 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; 2009 Sep 9-12; Dusseldorf.
25. Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, et al. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladri-bine. Acta Neurol Scand 2004 Jun; 109 (6): 390-2. (Pubitemid 38698175)
26. Janiec K, Wajgt A, Kondera-Anasz Z. Effect of immuno-suppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit 2001; 7 (1): 93-8. (Pubitemid 32125194)
27. Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, et al. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand 2010; 122 (6): 409-13.
28. Laugel B, Challier J, Siegfried C, et al. Cladribine exerts a modulatory effect on T-cell activation [abstract no. P80]. Mult Scler 2008; 14: S52-3.
29. Van Axel Castelli V, Trivieri G, Zucchelli I, et al. Char-acterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin. J Pharm Sci 2008 Sep; 97 (9): 3897-906.
30. Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet 1997 Feb; 32 (2): 120-31. (Pubitemid 27104411)
31. Comi G, Cook S, Giovannoni G, et al. Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebocontrolled CLARITY study [abstract no. P469 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2-9; Dusseldorf.
32. Vermersch P, Comi G, Cook S, et al. Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebocontrolled CLARITY study [abstract no. P817 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2-9; Dusseldorf.
33. Giovannoni G, Comi G, Cook S, et al. Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebocontrolled CLARITY study in patients with relapsing-remitting multiple sclerosis [abstract no. P471 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2-9; Dusseldorf.
34. Rammohan K, Comi G, Cook S, et al. Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study [abstract no. P02.186 plus poster]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10-17; Toronto (ON).
35. Giovannoni G, Comi G, Cook S, et al. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebocontrolled CLARITY study in patients with relapsing-remitting multiple sclerosis [abstract no. P470 plus poster]. 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2009 Sep 2-9; Dusseldorf.
36. Rammohan K, Comi G, Cook S, et al. Consistent efficacy of short-course cladribine tablets therapy across differing prognostic indicators for relapsing-remitting multiple sclerosis: Results from the phase III, double-blind, placebocontrolled, 96-week CLARITY study [abstract no. P441 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Goteborg.
37. Comi G, Giovannoni G, Rammohan K, et al. Consistent MRI benefits with short-course cladribine tablets therapy across the range of patients with relapsing-remitting multiple sclerosis in the double-blind, placebocontrolled, 96-week CLARITY study [abstract no. P403 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Goteburg.
38. Comi G, Cook S, Giovannoni G, et al. Consistent reductions in MRI activity with cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis in the CLARITY study [abstract no. P2375]. 14th Congresss of the European Federation of Neurological Societies; 2010 Sep 25-28; Geneva.
39. Giovannoni G, Comi G, Rammohan K, et al. Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study [abstract plus poster]. 14th Congress of the European Federation of Neurological Societies; 2010 Sep 25-28; Geneva.
40. Savic R, Munafo A, Karlsson M. The effect of cladribine tablets on disease progression in multiple sclerosis: a nonlinear mixed effect analysis [abstract no. P447 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Goteborg.
41. Havrdova E, Galetta S, Stefoski D, et al. Freedom from disease activity in multiple sclerosis. Neurology 2010 Apr 27; 74 Suppl. 3: S3-7.
42. Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler. Epub 2011 Jan 12.
43. Cook S, Vermersch P, Comi G, et al. Safety profile of clad-ribine tablets in the treatment of relapsing-remitting multiple sclerosis over 0-48 weeks compared with 48-96 weeks in the phase III, double-blind, placebocontrolled CLARITY study [abstract no. P817 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010 Oct 13-16; Goteborg.
44. European Medicines Agency. Refusal of the marketing authorisation for Movectro (cladribine) [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/Summary-of-opinion-Initial-author isation/human/001197/WC500101072.pdf [Accessed 2011 Jan 28]